NDA 215256 · Novo
Wegovy
Semaglutide · Subcutaneous
NovelBreakthrough therapyAccelerated approvalPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Jun 4, 2021
Approved uses
8
Original approval plus efficacy supplements
Registered trials
626
187 Phase 3, 161 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ) and Nonclinical Toxicology ( 13.1 )] . • WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of WEGOVY and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid...
What it is approved for
From the label in effect Apr 23, 2024.
WEGOVY is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use • WEGOVY contains semaglutide. Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (1) . • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition (1) . Limitations of Use: • Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended (1).
Mechanism: Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. Animal studies show that semaglutide distributed to and activated neurons in brain regions involved in regulation of food intake. The exact mechanism of cardiovascular risk reduction has not been established.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 19, 2026 Supplement 29 · Efficacy LetterLabelMedication Guide
- Nov 21, 2025 Supplement 23 · Efficacy LetterLabel
- Aug 15, 2025 Supplement 24 · Efficacy · priority review Breakthrough therapyLabelLetter
- Nov 27, 2024 Supplement 15 · Efficacy LetterLabel
- Mar 8, 2024 Supplement 11 · Efficacy · priority review LabelLetterReview
- Jul 21, 2023 Supplement 7 · Efficacy LetterLabel
- Dec 23, 2022 Supplement 5 · Efficacy · priority review LabelLetter
- Jun 4, 2021 Original approval · Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated · priority review NovelAccelerated approvalLabelLetterReview
12 products under this application
- WEGOVY · SEMAGLUTIDE 1MG/0.5ML (1MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- WEGOVY · SEMAGLUTIDE 0.25MG/0.5ML (0.25MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- WEGOVY · SEMAGLUTIDE 2.4MG/0.75ML (2.4MG/0.75ML) · SOLUTION, SUBCUTANEOUS · Prescription
- WEGOVY · SEMAGLUTIDE 2.4MG/0.75ML (2.4MG/0.75ML) · SOLUTION, SUBCUTANEOUS · Prescription
- WEGOVY · SEMAGLUTIDE 1MG/0.5ML (1MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- WEGOVY · SEMAGLUTIDE 0.25MG/0.5ML (0.25MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- WEGOVY · SEMAGLUTIDE 0.5MG/0.5ML (0.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- WEGOVY HD · SEMAGLUTIDE 7.2MG/0.75ML (7.2MG/0.75ML) · SOLUTION, SUBCUTANEOUS · Prescription
- WEGOVY FLEXTOUCH · SEMAGLUTIDE 9.6MG/3ML (3.2MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- WEGOVY · SEMAGLUTIDE 1.7MG/0.75ML (1.7MG/0.75ML) · SOLUTION, SUBCUTANEOUS · Prescription
- WEGOVY · SEMAGLUTIDE 1.7MG/0.75ML (1.7MG/0.75ML) · SOLUTION, SUBCUTANEOUS · Prescription
- WEGOVY · SEMAGLUTIDE 0.5MG/0.5ML (0.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Semaglutide" as an intervention, any sponsor and status, largest first.
- A Study of Cardiovascular Events iN Diabetes PlusPivotal-lookingActive, not recruiting
University of OxfordAcademic, hospital or other
NCT05441267 · 21,296 participants · Start Mar 13, 2023 · Primary completion Aug 17, 2028
Drug: Semaglutide Oral Tablet; Placebo oral tablet · For: Diabetes Mellitus, Type 2
Sites: Oxford, United Kingdom
- Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03574597 · 17,604 participants · Start Oct 24, 2018 · Primary completion Jun 21, 2023
Drug: Semaglutide; Placebo (semaglutide) · For: Overweight; Obesity
Sites: Birmingham, Alabama; Montgomery, Alabama; Glendale, Arizona · 833 sites in all
- A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03914326 · 9,651 participants · Start Jun 17, 2019 · Primary completion Aug 23, 2024
Drug: Semaglutide; Placebo (semaglutide) · For: Diabetes Mellitus, Type 2
Sites: Montgomery, Alabama; Little Rock, Arkansas; Searcy, Arkansas · 492 sites in all
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05669755 · 7,101 participants · Start Mar 1, 2023 · Primary completion Sep 1, 2027
Drug: Cagrilintide; Semaglutide and 1 more · For: Cardiovascular Disease
Sites: Birmingham, Alabama; Montgomery, Alabama; Scottsdale, Arizona · 633 sites in all
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05390892 · 6,000 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 1, 2029
Drug: SGLT2 inhibitor; GLP-1 receptor agonist · For: Type2Diabetes; ASCVD
Sites: Huntsville, Alabama; Scottsdale, Arizona; Los Angeles, California · 36 sites in all
- A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney DiseasePivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03819153 · 3,533 participants · Start Jun 17, 2019 · Primary completion Jan 9, 2024
Drug: Semaglutide; Placebo (semaglutide) · For: Diabetes Mellitus, Type 2
Sites: Tuscumbia, Alabama; Chula Vista, California; Concord, California · 413 sites in all
- A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05567796 · 3,400 participants (planned) · Start Nov 1, 2022 · Primary completion Oct 30, 2024
Drug: Cagrilintide; Semaglutide and 2 more · For: Obesity
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 256 sites in all
- Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01720446 · 3,297 participants · Start Feb 21, 2013 · Primary completion Mar 15, 2016
Drug: semaglutide; semaglutide and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Chandler, Arizona; Anaheim, California · 253 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Wegovy (Semaglutide)
2024 spending
$301M
Beneficiaries
52,961
211,575 claims
Per beneficiary
$5,689
$602.09 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $199,774 |
| 2024 | $301,283,291 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Tan HC, Dampil OA, Marquez MM · J ASEAN Fed Endocr Soc 2022 · Meta-Analysis, Systematic Review
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
Wharton S, Lingvay I, Bogdanski P, et al. · N Engl J Med 2025 · Clinical Trial, Phase II, Multicenter Study
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, Horn DB, le Roux CW, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Yao H, Zhang A, Li D, et al. · BMJ 2024 · Systematic Review, Network Meta-Analysis
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Davies M, Færch L, Jeppesen OK, et al. · Lancet 2021 · Clinical Trial, Phase III, Multicenter Study
- Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Ryan DH, Lingvay I, Deanfield J, et al. · Nat Med 2024 · Randomized Controlled Trial, Multicenter Study
Sponsor: Novo · Also marketed as Wegovy Hd, Wegovy Flextouch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.